Form 3 - Initial statement of beneficial ownership of securities:
SEC Accession No. 0001209191-21-005143
Filing Date
2021-01-25
Accepted
2021-01-25 17:27:01
Documents
2
Period of Report
2021-01-22

Document Format Files

Seq Description Document Type Size
1 FORM 3 SUBMISSION doc3.html 3  
1 FORM 3 SUBMISSION doc3.xml 3 1548
2 POA DOCUMENT poa.txt EX-24.3_957491 3348
  Complete submission text file 0001209191-21-005143.txt   6405
Mailing Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121
Business Address 6310 NANCY RIDGE DRIVE SUITE 101 SAN DIEGO CA 92121 858-752-6170
Cidara Therapeutics, Inc. (Issuer) CIK: 0001610618 (see all company filings)

EIN.: 461537286 | State of Incorp.: DE | Fiscal Year End: 1231
SIC: 2836 Biological Products, (No Diagnostic Substances)

Mailing Address C/O CIDARA THERAPEUTICS, INC. 6310 NANCY RIDGE DR STE 101 CA 92121
Business Address
Canale-Theakston Carin (Reporting) CIK: 0001841613 (see all company filings)

Type: 3 | Act: 34 | File No.: 001-36912 | Film No.: 21550860